Sign in
CompletedPhase 4

N-Acetylcysteine for Smoking Cessation in Tobacco and Cannabis Co-Use

Key facts

Who runs it
Ellen Herbst
Where
San Francisco, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 4
People taking part
41 people enrolled
Started
25 Aug 2021
Ended
30 Jun 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • N-Acetyl cysteine
  • Placebo comparator
  • Cognitive behavioral therapy (CBT)
Record updated
11 August 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Participants will be male and female smokers ages 18 and over who: 1) have smoked 2 cigarettes per day in 15 of the past 30 days, or an average of 1 cigarettes per day for the past 30 days; 2) endorse the use of cannabis within the past 30 days, reported by Timeline Follow-Back (TLFB), and have positive urine tetrahydrocannabinol (THC) at Week 0 or up to 30 days prior; 3) meet criteria for tobacco use disorder (TUD) in the past 12 months per Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), assessed by medical record review and clinical assessment; and 4) consent to receive interventions to stop smoking cigarettes and reducing cannabis use. Although co-users can use tobacco and cannabis simultaneously (i.e. in "spliffs") and other forms of nicotine and tobacco, participants must smoke combustible cigarettes that are not mixed with cannabis on a daily basis to participate. Individuals of childbearing potential (ages 18-55) must have a negative urine pregnancy test at the time of screening. Individuals who have been prescribed bupropion for depression, not smoking cessation, are eligible to participate in this study. All participants must be California residents (Veterans enrolled in VA healthcare in another state are eligible)

Who cannot take part

  • Psychotic disorders, bipolar disorder, neurocognitive disorder, or other psychiatric or medical conditions judged by the PI to be unstable in the past 30 days, based on screening results and/or medical record review. 2) Concurrent participation in another pharmacological tobacco cessation study. 3) Individuals who are pregnant or lactating. 4) Non-study NAC use at enrollment or at any time during the study period. 5) Use of medications for TUD (NRT, bupropion, or varenicline) at enrollment or at any time during the study period. 6) A suicide attempt or suicidal ideation with intent in the 30 days prior to enrollment. 7) Non-residents of California or Veterans in another state who are not enrolled in VA healthcare

Where in United States

  • San Francisco Veterans Affairs Medical CenterSan Francisco, United States

About the trial

What the trial wants to find out

Tobacco and cannabis co-use is a common and growing public health problem, especially in states that have legalized cannabis. There are no pharmacologic treatments for co-occurring tobacco and cannabis use. Co-use may make quitting either substance more difficult, given the synergistic effects of cannabis and nicotine on neurobiological systems that mediate reward and shared cues reinforcing co-use. N-acetylcysteine (NAC), an FDA-approved medication and over-the-counter supplement, has shown promise in animal studies and randomized controlled trials (RCTs) in reducing tobacco and cannabis craving and use.

The 2 groups in the trial

  • N-acetyl cysteine (NAC) & cognitive behavioral therapyTreatment being tested

    N-acetyl cysteine (NAC) \& cognitive behavioral therapy experimental arm consists of 30 regular cigarette smokers and cannabis users with current TUD, who will be randomized to receive N-acetyl cysteine 3600 mg per day over 8 weeks to experimental arm. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and cannabis use.

    Treatment: N-Acetyl cysteine and Cognitive behavioral therapy (CBT)

  • Placebo Comparator: Placebo & cognitive behavioral therapyPlacebo, for comparison

    Placebo comparator \& cognitive behavioral therapy arm consists of 30 regular cigarette smokers and cannabis users with current TUD, who will be randomized to receive placebo over 8 weeks. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and cannabis use.

    Treatment: Placebo comparator and Cognitive behavioral therapy (CBT)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
N-Acetylcysteine for Smoking Cessation in Tobacco and Cannabis Co-Use: A Randomized Controlled Trial
Publications
Record updated
11 August 2026